Mts105 for Advanced Hepatocellular Carcinoma

You may not qualify if:

• Any known active intracranial metastases, or brain metastases that have been treated for less than 4 weeks.
• Recent Antitumor Therapy:
• Treatment with any immune checkpoint inhibitor within 4 weeks (28 days) prior to the first dose.
• Received any investigational drug within 4 weeks prior to the first dose.
• Received localized therapy for hepatocellular carcinoma (HCC), including but not limited to arterial chemoembolization (TACE), arterial infusion chemotherapy (HAIC), Y-90 radioembolization, ablative therapy, or stereotactic radiation therapy (SBRT), within 4 weeks prior to the first dose.
• Received other anticancer therapies, such as multi-targeted tyrosine kinase inhibitors (mTKIs) and/or anti-VEGF therapies, within 3 weeks.
• Received non-specific immunomodulatory therapy, including but not limited to interleukin, interferon, thymidine, etc., within 2 weeks prior to the first dose.
• Received herbal or proprietary Chinese medicine for antitumor indications within 1 week prior to the first dose.
• Previously received experimental treatment targeting GPC3 (patients may be enrolled if they remain positive for GPC3 upon testing).
• History of liver transplantation or hematopoietic stem cell transplantation.
• Unresolved toxicity from prior anticancer therapy (\> grade 1, according to CTCAE v5.0).
• Major surgery (other than biopsy) within 28 days prior to the first dose.
• Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg).
• Class III-IV heart failure by New York Heart Association (NYHA) criteria within 6 months prior to the first dose, unstable angina, myocardial infarction, bypass surgery, stent placement, cerebral infarction, or clinically significant valvular heart disease.
• QTcF ≥ 450 ms in men and ≥ 470 ms in women (by Fridericia formula).
• +11 more criteria